SDZ 210-086

SDZ 210-086
[[File:|frameless|220px|alt=|Chemical structure of SDZ 210-086]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

SDZ 210-086 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily known for its role as a selective antagonist of the neurokinin-1 receptor (NK1 receptor), which is involved in various physiological processes, including the modulation of pain and the regulation of mood.

Pharmacology

SDZ 210-086 acts by selectively blocking the NK1 receptor, which is a receptor for the neuropeptide substance P. Substance P is a key player in the transmission of pain signals and is also implicated in the pathophysiology of depression and anxiety disorders. By inhibiting the action of substance P, SDZ 210-086 may have potential therapeutic applications in the treatment of these conditions.

Mechanism of Action

The NK1 receptor is a G protein-coupled receptor that, upon binding with substance P, activates intracellular signaling pathways that lead to the sensation of pain and the modulation of mood. SDZ 210-086 binds to the NK1 receptor, preventing substance P from exerting its effects, thereby potentially reducing pain perception and alleviating symptoms of mood disorders.

Clinical Research

Research on SDZ 210-086 has primarily focused on its potential use in treating chronic pain, depression, and anxiety. Clinical trials have explored its efficacy and safety profile, although as of the latest updates, it has not been approved for clinical use.

Chemical Properties

SDZ 210-086 is characterized by its specific chemical structure, which allows it to selectively bind to the NK1 receptor. Detailed studies of its chemical properties are essential for understanding its pharmacokinetics and pharmacodynamics.

Potential Applications

The potential applications of SDZ 210-086 extend beyond pain management and mood disorders. Ongoing research is investigating its role in other conditions where substance P and NK1 receptors are implicated, such as chemotherapy-induced nausea and vomiting (CINV).

Safety and Side Effects

As with any pharmacological agent, the safety profile of SDZ 210-086 is a critical aspect of its development. Studies have reported various side effects, which need to be carefully evaluated in the context of its therapeutic benefits.

Also see

• Neurokinin-1 receptor antagonist
• Substance P
• Chronic pain management
• Depression treatment
• Anxiety disorder

Receptor Antagonists
Receptor Type	Example Antagonists
Adrenergic receptor	Propranolol, Prazosin
Cholinergic receptor	Atropine, Scopolamine
Dopamine receptor	Haloperidol, Clozapine
Histamine receptor	Ranitidine, Diphenhydramine
Serotonin receptor	Ondansetron, Risperidone
Glutamate receptor	Memantine, Ketamine
GABA receptor	Flumazenil, Bicuculline
Opioid receptor	Naloxone, Naltrexone
Angiotensin receptor	Losartan, Valsartan